Michael Okunewitch
Stock Analyst at Maxim Group
(0.13)
# 4,738
Out of 5,090 analysts
386
Total ratings
33.3%
Success rate
-6.9%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology | Maintained: Buy | $4 | $0.7003 | +471.18% | 14 | Oct 28, 2026 | |
| EVAX Evaxion | Maintained: Buy | $10 → $14 | $3.71 | +277.36% | 5 | Oct 22, 2026 | |
| KYNB Kyntra Bio | Initiated Coverage: Buy | $35 | $5.21 | +571.79% | 1 | Oct 13, 2026 | |
| HCWB HCW Biologics | Reiterated: Buy | $8 | $1.16 | +589.66% | 26 | Oct 9, 2026 | |
| BRTX BioRestorative Therapies | Downgraded: Hold | n/a | $1.53 | - | 24 | Oct 6, 2026 | |
| AIDX 20/20 Biolabs | Rated: Buy | n/a | $0.2702 | - | 3 | Oct 2, 2026 | |
| LGVN Longeveron | Reiterated: Hold | n/a | $1.43 | - | 26 | Sep 18, 2026 | |
| OCGN Ocugen | Reiterated: Buy | $8 | $0.8151 | +881.47% | 24 | Sep 16, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $55 | $35.49 | +54.97% | 17 | Sep 15, 2026 | |
| KPRX Kiora Pharmaceuticals | Reiterated: Buy | $12 | $2.34 | +412.82% | 33 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.605 | +726.45% | 16 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.1664 | - | 4 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $153.66 | +30.16% | 14 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $12.10 | +147.93% | 28 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.83 | +283.56% | 13 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.9515 | +215.29% | 16 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $11.84 | +68.92% | 12 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 | $153.57 | +7.44% | 24 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.15 | +334.78% | 13 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.993 | - | 8 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $12 | $1.50 | +700.00% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.9788 | +1,432.49% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.02 | - | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.3955 | n/a | 28 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6.9 | $1.25 | n/a | 6 | Sep 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.35 | n/a | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.82 | n/a | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3305 | n/a | 4 | May 9, 2023 |
Citius Oncology
Oct 28, 2026
Maintained: Buy
Price Target: $4
Current: $0.7003
Upside: +471.18%
Evaxion
Oct 22, 2026
Maintained: Buy
Price Target: $10 → $14
Current: $3.71
Upside: +277.36%
Kyntra Bio
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $5.21
Upside: +571.79%
HCW Biologics
Oct 9, 2026
Reiterated: Buy
Price Target: $8
Current: $1.16
Upside: +589.66%
BioRestorative Therapies
Oct 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.53
Upside: -
20/20 Biolabs
Oct 2, 2026
Rated: Buy
Price Target: n/a
Current: $0.2702
Upside: -
Longeveron
Sep 18, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.43
Upside: -
Ocugen
Sep 16, 2026
Reiterated: Buy
Price Target: $8
Current: $0.8151
Upside: +881.47%
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $55
Current: $35.49
Upside: +54.97%
Kiora Pharmaceuticals
Aug 20, 2026
Reiterated: Buy
Price Target: $12
Current: $2.34
Upside: +412.82%
Aug 20, 2026
Reiterated: Buy
Price Target: $5
Current: $0.605
Upside: +726.45%
Aug 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.1664
Upside: -
Aug 14, 2026
Reiterated: Buy
Price Target: $200
Current: $153.66
Upside: +30.16%
Aug 14, 2026
Reiterated: Buy
Price Target: $30
Current: $12.10
Upside: +147.93%
Aug 13, 2026
Reiterated: Buy
Price Target: $7
Current: $1.83
Upside: +283.56%
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $0.9515
Upside: +215.29%
Aug 7, 2026
Reiterated: Buy
Price Target: $20
Current: $11.84
Upside: +68.92%
Aug 6, 2026
Reiterated: Buy
Price Target: $165
Current: $153.57
Upside: +7.44%
Jul 13, 2026
Reiterated: Buy
Price Target: $5
Current: $1.15
Upside: +334.78%
May 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.993
Upside: -
Apr 9, 2026
Rated: Buy
Price Target: $10 → $12
Current: $1.50
Upside: +700.00%
Mar 25, 2026
Reiterated: Buy
Price Target: $15
Current: $0.9788
Upside: +1,432.49%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.02
Upside: -
Sep 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.3955
Upside: n/a
Sep 13, 2025
Reiterated: Hold
Price Target: $6.9
Current: $1.25
Upside: n/a
Mar 3, 2025
Reiterated: Buy
Price Target: $12
Current: $2.35
Upside: n/a
Sep 13, 2024
Reiterated: Buy
Price Target: $12
Current: $2.82
Upside: n/a
May 9, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.3305
Upside: n/a